Literature DB >> 6273414

The regulatory component of adenylate cyclase. Purification and properties of the turkey erythrocyte protein.

E Hanski, P C Sternweis, J K Northup, A W Dromerick, A G Gilman.   

Abstract

The regulatory component (G/F) of adenylate cyclase has been purified from turkey erythrocyte plasma membranes by adaptation of procedures developed for purification of the rabbit liver protein. The major modifications entail inclusion of high concentrations of NaCl to facilitate extraction and reconstitution of the protein. A typical preparation yields 200 micrograms of protein with a reconstitutive specific activity of 3-4 mumol . min-1 mg-1. Turkey erythrocyte G/F contains two putative subunits of 35,000 and 45,000 daltons. The 52,000-dalton polypeptide that appears to be a component of rabbit liver G/F is lacking. In solution, G/F behaves as a particle with Mr = 81,000. This value is reduced to 50,000 in the presence of activating ligands, suggesting dissociation of subunits. Activation of G/F by guanine nucleotide analogs is markedly accelerated in the presence of high concentrations of Mg2+. Reconstitutive and physical properties of the protein are also affected by fluoride. Cyc- S49 lymphoma membranes reconstituted with turkey erythrocyte G/F acquire properties that are characteristic of the turkey adenylate cyclase system; at least certain differing characteristics of adenylate cyclase systems are thus dictated by the nature of their G/F.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6273414

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  The beta-adrenoceptor-adenylate cyclase complex. From model to biochemical reality.

Authors:  A P Ijzerman; H Timmerman
Journal:  Pharm Weekbl Sci       Date:  1986-08-22

2.  Treatment of human platelets with trypsin, thrombin, or collagen inhibits the pertussis toxin-induced ADP-ribosylation of a 41-kDa protein.

Authors:  E G Lapetina; B Reep; K J Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

3.  Subcellular distributions of calcium/calmodulin-stimulated and guanine nucleotide-regulated adenylate cyclase activities in the cerebral cortex.

Authors:  S T Bissen; T Ueda
Journal:  Neurochem Res       Date:  1986-03       Impact factor: 3.996

Review 4.  Adenylate cyclase and membrane fluidity. The repressor hypothesis.

Authors:  R Salesse; J Garnier
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

5.  Inactivation of the guanine nucleotide regulatory site mediating inhibition of the adenylate cyclase in hamster adipocytes.

Authors:  K Aktories; G Schultz; K H Jakobs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

6.  Erythroid spectrin, brain fodrin, and intestinal brush border proteins (TW-260/240) are related molecules containing a common calmodulin-binding subunit bound to a variant cell type-specific subunit.

Authors:  J R Glenney; P Glenney; K Weber
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

7.  Hormone receptor modulates the regulatory component of adenylyl cyclase by reducing its requirement for Mg2+ and enhancing its extent of activation by guanine nucleotides.

Authors:  R Iyengar; L Birnbaumer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

8.  Functional reconstitution of beta-adrenergic receptors and the stimulatory GTP-binding protein of adenylate cyclase.

Authors:  S E Pedersen; E M Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

9.  Catalytic unit of adenlyate cyclase: purification and identification by affinity crosslinking.

Authors:  E Pfeuffer; R M Dreher; H Metzger; T Pfeuffer
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

10.  Hydrodynamic properties of muscarinic acetylcholine receptors solubilized from rat forebrain.

Authors:  C P Berrie; N J Birdsall; K Haga; T Haga; E C Hulme
Journal:  Br J Pharmacol       Date:  1984-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.